Ranbaxy introduced its products to around 350 doctors during a formal launch recently. The company will focus on therapy areas such as anti-infectives, gastro-intestinal, cholesterol lowering and anti-allergic therapeutic categories, said Sanjeev I Dani, senior vice president and regional director for Asia and CIS countries.
Ranbaxy is the first Indian company to establish a major presence in West Asia. It is located in 11 countries and has a product pipeline of 160 drug approvals. The pharma market in the region is valued in excess of $10 billion, with a growth rate of 15-18 per cent, according to industry sources.
Ranbaxy has a presence in the UAE, Oman, Kuwait, Bahrain, Qatar, Lebanon, Iran, Iraq, Jordan, Syria and Afghanistan.
UAE is Ranbaxy's single largest market in West Asia. Ranbaxy sells 20 products in the UAE, two of which feature among the top 50 pharmaceutical products. Ranbaxy is ranked 12th and is the fastest growing among the top 15 pharmaceutical companies in the UAE. It has been the leading private sector company in Oman in the last three years.